Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Exhibition Road, London SW7 2AZ, UK.
Sci Transl Med. 2012 Jun 6;4(137):137rv6. doi: 10.1126/scitranslmed.3004244.
The complex metabolic relationships between the host and its microbiota change throughout life and vary extensively between individuals, affecting disease risk factors and therapeutic responses through drug metabolism. Elucidating the biochemical mechanisms underlying this human supraorganism symbiosis is yielding new therapeutic insights to improve human health, treat disease, and potentially modify human disease risk factors. Therapeutic options include targeting drugs to microbial genes or co-regulated host pathways and modifying the gut microbiota through diet, probiotic and prebiotic interventions, bariatric surgery, fecal transplants, or ecological engineering. The age-associated co-development of the host and its microbiota provides a series of windows for therapeutic intervention from early life through old age.
宿主与其微生物组之间复杂的代谢关系在整个生命周期中发生变化,并且在个体之间广泛变化,通过药物代谢影响疾病风险因素和治疗反应。阐明这种人类超级生物体共生关系的生化机制正在产生新的治疗见解,以改善人类健康、治疗疾病,并可能改变人类疾病风险因素。治疗选择包括针对微生物基因或共调控宿主途径的药物,以及通过饮食、益生菌和益生元干预、减肥手术、粪便移植或生态工程来改变肠道微生物组。宿主与其微生物组的年龄相关共同发育为从婴儿期到老年的治疗干预提供了一系列机会。